USE OF IMATINIB TO TREAT HEPATIC FIBROSIS
There is a huge potential economic impact of establishing a treatment for hepatic fibrosis. Progressive fibrosis of the liver often results in organ failure leading to death or the need for transplantation. These diseases affect hundreds of millions in the United States …
NOVEL LIVE ATTENUATED INFLUENZA VIRUS VACCINES
This technology takes advantage of the species-specific expression of miRNAs to generate live attenuated influenza virus vaccines (LAIVs) alleviating all manufacturing constraints and the necessity of relying on cold-adapted mutants. This technology is enabled by the silent insertion of perfect miRNA target …
MODIFIED VERO CELLS WITH SUPPRESSED INNATE IMMUNE RESPONSES AND ENHANCED VIRUS PRODUCTION
Dr. Chris Basler and colleagues have developed a stable cell line with enhanced virus replication and production efficiency. The Vero 76 cell line (ATCC No. CCL-1587) has been widely used for cell-based research and product development (1, 2, 4). Several characteristics of …
Future of health: LifeMap grabs $5M, partners with Mount Sinai School of Medicine on big data-powered mobile health platform
For better or for worse, we’re living in an era of near constant self-quantification. From wi-fi enabled bathroom scales, to activity monitoring wristbands, to personal DNA sequencing, consumers are gathering more data about their health and wellness than at any time in …
Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease
SPRING HOUSE, Pa., May 5, 2014 /PRNewswire/ — Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC), Prometheus Laboratories Inc. (Prometheus), Mayo Clinic, Rochester, Minnesota (Mayo Clinic), Centre Hospitalier Regional Universitaire …
A PROTOCOL FOR GENERATION OF FUNCTIONAL MYELOID-DERIVED SUPPRESSOR CELLS FROM EMBRYONIC STEM CELLS AND HEMATOPOIETIC STEM CELLS
To date, a major limiting factor for the use of MDSCs in certain therapies – in pathological settings where deleterious or excessive immune responses need to be avoided or reduced – is the source of MDSCs. Mount Sinai researchers demonstrated efficient in …
ANTIBODIES TARGETING FOLLICLE STIMULATING HORMONE FOR USE IN OSTEOPOROSIS TREATMENT AND PREVENTION
A new paradigm for osteoporosis prevention and treatment was described by Dr. Mone Zaidi, Director of the Mount Sinai Bone Program at the Icahn School of Medicine at Mount Sinai. By blocking follicle-stimulating hormone (FSH) in pre-clinical models of menopause using an …
HARNESSING THE IMMUNOSUPPRESSIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS (MDSC) TO TREAT OR PREVENT AUTOIMMUNE DISEASES AND GRAFT-VERSUS-HOST DISEASE (GVHD)
Emerging evidence suggests that MDSCs have great potential as an immune intervention modality in both transplantation and autoimmune disease settings. Mount Sinai investigators demonstrated their utility in both GVHD and Type 1 Diabetes. Coupled with a suite of other pending patent applications …
Auven Therapeutics and BELLUS Health Announce License Agreement with Mount Sinai for KIACTA in Sarcoidosis
May 2, 2014 – Auven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc. (TSX: BLU), a drug development company focused on rare diseases, today announced that Auven has entered into a license …
NOVEL BROMODOMAIN (BRD4) SMALL MOLECULE INHIBITORS FOR TARGETED TREATMENT OF CANCER
Bromodomain-containing proteins function as chromatin modifiers and mediators of protein-protein interactions, controlling gene expression. BRDs have been functionally implicated in numerous disease processes, including cancer, and small molecule inhibitors have been developed with some advancing to early clinical trials in cancer. BRD4 …